Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 8/20 | 0.78 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.78 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.78 |
| ▸ | MRGPRX2 | Q96LB1 | 4/20 | 0.78 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.78 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.78 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.78 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.69 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.69 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29416620 | 1.00 | OPRD1 (0.78) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Codeine SCHEMBL3475523 | 0.91 | OPRD1 (0.88) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL29011591 | 0.88 | OPRM1 (0.70) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Codeine SCHEMBL1560699 | 0.88 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Codeine SCHEMBL12638890 | 0.88 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Codeine SCHEMBL16922135 | 0.88 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Codeine SCHEMBL16922140 | 0.88 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Codeine SCHEMBL21077535 | 0.88 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Codeine SCHEMBL1276342 | 0.88 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Codeine SCHEMBL8218174 | 0.88 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0844241-B1 | INHIBITOR FOR NARCOTIC ANALGETIC DEPENDENCE/RESISTANCE ACQUISITION | DAIICHI SEIYAKU CO (JP) | 2003-01-22 | — | — | EP | claimed |
| US-6107330-A | CONCURRENT ADMINISTERING A 2-OXO-1-PYRROLIDINYL COMPOUND | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-08-22 | — | — | US | claimed |
| EP-0844241-A1 | INHIBITOR FOR NARCOTIC ANALGETIC DEPENDENCE/RESISTANCE ACQUISITION | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1998-05-27 | — | — | EP | claimed |
| US-20250281680-A1 | DRUG-ELUTING SURGICAL ARTICLES AND RELATED METHODS | BIOSAPIEN INC (US) | 2025-09-11 | — | — | US | disclosed |
| US-20250177290-A1 | DRUG-ELUTING SURGICAL ARTICLES AND METHODS OF USE THEREOF | BioSapien Inc. | 2025-06-05 | — | — | US | disclosed |
| EP-4522238-A2 | DRUG-ELUTING SURGICAL ARTICLES AND METHODS OF USE THEREOF | Biosapien Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| CN-119546355-A | Drug eluting surgical article and method of use | 生物智慧公司 | 2025-02-28 | — | — | CN | disclosed |
| EP-3899995-B1 | DRUG-ELUTING SURGICAL ARTICLES AND RELATED METHODS | BIOSAPIEN INC (US) | 2024-09-04 | — | — | EP | disclosed |
| US-11969527-B2 | Drug-eluting biomaterials and related methods | BioSapien Inc. (US) | 2024-04-30 | — | — | US | disclosed |
| EP-3597262-B1 | FORMULATION FOR INTRACUTANEOUS INJECTION | XERIS PHARMACEUTICALS INC (US) | 2023-12-27 | — | — | EP | disclosed |
| WO-2023220400-A2 | DRUG-ELUTING SURGICAL ARTICLES AND METHODS OF USE THEREOF | BioSapien Inc. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20030082230-A1 | Chronotherapeutic dosage forms and methods of treatment using chronotherapy | PENWEST PHARMACEUTICALS COMPANY | 2003-05-01 | — | — | US | disclosed |
| EP-0844241-B1 | INHIBITOR FOR NARCOTIC ANALGETIC DEPENDENCE/RESISTANCE ACQUISITION | DAIICHI SEIYAKU CO (JP) | 2003-01-22 | — | — | EP | disclosed |
| US-20030004176-A1 | Prevention of addiction in pain management | BROOKHAVEN SCIENCE ASSOCIATES LLC | 2003-01-02 | — | — | US | disclosed |
| US-20020187996-A1 | Prevention of addiction in pain management | BROOKHAVEN SCIENCE ASSOCIATES | 2002-12-12 | — | — | US | disclosed |
| US-6107330-A | CONCURRENT ADMINISTERING A 2-OXO-1-PYRROLIDINYL COMPOUND | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-08-22 | — | — | US | disclosed |
| EP-0844241-A1 | INHIBITOR FOR NARCOTIC ANALGETIC DEPENDENCE/RESISTANCE ACQUISITION | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1998-05-27 | — | — | EP | disclosed |
| US-5378474-A | Pellet having a core including at least one highly soluble active ingredient and a coating partially soluble at high acidity; opiod drugs | F. H. FAULDING & CO. LIMITED (AU) | 1995-01-03 | — | — | US | disclosed |
| US-5330766-A | Water soluble active ingredient core coated with matrix and enteric polymers; high speed, uniform release | F. H. FAULDING & CO. LIMITED (AU) | 1994-07-19 | — | — | US | disclosed |
| US-5202128-A | Oral administering | F. H. FAULDING & CO. LIMITED (AU) | 1993-04-13 | — | — | US | disclosed |